The Merck-Schering Plough merger is over a year old, and has not exactly filled investors with hope. The economies of scale have not become apparent, and the only tangible outcome so far is the thousands of jobs lost and dozens of sites closed in the name of cost-cutting. Moreover, while the company continues to sit on a mountain of cash (thereby giving it a healthy Altman score of 2.4), earnings are meager, resulting in an eye-popping PE score of 120. Even competitor Pfizer, known for growth by merger, has a PE only 1/10th as high. While Merck has been a staple of blue chip portfolios for decades thanks to its healthy dividend (currently yielding over 4.5%), a valuation like this can only be supported for so long by the price.

Enter a stock symbol to view that company's Altman Z-Score if it is a manufacturing company, or its Altman Z"-Score, if it is a non-financial, non-manufacturing company, and to view message board posts for that stock (Scores are available for premium members).

Below is a list of today's twenty-five most distressed stocks (according to their Altman Z-Score or Z''-Score, respectively) with a share price of $5 or higher. For details on how this ranking list is compiled, please click here.